Human therapeutics company Amgen (NASDAQ:AMGN) revealed on Friday the receipt of the US Food and Drug Administration (FDA) supplemental Biologics License Application (sBLA) for Nplate (romiplostim) for the treatment of paediatric immune thrombocytopenia (ITP).
ITP is a rare, serious autoimmune disease characterised by low platelet counts in the blood (a condition known as thrombocytopenia) and impaired platelet production.
The company said the US FDA approved the supplemental Biologics License Application (sBLA) for Nplate (romiplostim) for the treatment of pediatric patients one year of age and older with immune thrombocytopenia (ITP) for at least six months who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.
This US FDA approval was based on the company's two placebo-controlled studies – Phase 3 and Phase 1/2 – evaluating the safety and efficacy of Nplate in paediatric patients. In the Phase 3 study, published in The Lancet, rates of overall platelet response were increased with the Nplate group (71%) compared with placebo (20%). In the two placebo-controlled trials, adverse reactions with an incidence of > 25% in the Nplate arm were contusion, upper respiratory tract infection and oropharyngeal pain.
According to the company, Nplate is a thrombopoietin (TPO) receptor agonist that mimics the body's natural TPO and is designed to increase platelet counts in patients with chronic immune thrombocytopenia (ITP). Nplate is approved in 67 countries, including Canada, Australia and Japan.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study
Precision Epigenomics partners with TruDiagnostic
Modalis partners with Ginkgo Bioworks
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002